Insulin therapy in children and adolescents

Endocrinology and Metabolism Clinics of North America

Volumn 41, Issue 1, 2012, Pages 145-160

  Tamborlane, William V ^a   Sikes, Kristin A ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale Children's Diabetes Program   (United States)

Author keywords

Insulin therapy; MDI; Pediatrics; Pump therapy

Indexed keywords

HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; SHORT ACTING INSULIN;

ADD ON THERAPY; ADOLESCENT; BOLUS INJECTION; CHILD; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG ABSORPTION; DRUG FORMULATION; HORMONE SUBSTITUTION; HUMAN; INJECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN INFUSION; INSULIN PUMP; INSULIN RELEASE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PEDIATRICS; PRIORITY JOURNAL; REVIEW; SIMULATION;

ADOLESCENT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS;

EID: 84860622174     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2012.01.002     Document Type: Review

References (30)

1. DCCT Research Group. The effects of intensive diabetes treatment on the development and progression of long-term complication in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. N Engl J Med 1993, 329:977-986.
2. The DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. J Pediatr 1994, 125:177-188.
3. DCCT Research Group, EDIC Research Group Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the diabetes control and complications trial (DCCT). J Pediatr 2001, 139(6):804-812.
4. Silverstein J., Klingensmith G., Copeland K., et al. Care of children and adolescents with type 1 diabetes. A statement of the American Diabetes Association. Diabetes Care 2005, 28(1):186-212.
5. Rewers M., Pihoker C., Donaghue K., et al. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 2009, 10(Suppl 12):71-81.
6. Vajo Z., Fawcett J., Duckworth W.C. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev 2001, 22:706-717.
7. Swan K.L., Weinzimer S.A., Steil G., et al. Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with T1DM. Diabetes Care 2001, 31:41-46.
8. Weinzimer S.A., Ternand C., Campbell H., et al. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care 2008, 31(2):210-215.
9. Van Bon A.C., Bode B.W., Sert-Langeron C., et al. Insulin glulisine compared to insulin aspart and insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized control trial. Diabetes Technol Ther 2011, 13(6):607-614.
10. Bangstad H.J., Danne T., Deeb L.C., et al. Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes 2009, 10(Suppl 12):82-99.
11. Lepore M., Panpanelli S., Fanelli C., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000, 49:2142-2148.
12. Chase P., Arslanian S., White N.H., et al. Insulin glargine vs. intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes. J Pediatr 2008, 153:547-553.
13. Danne T., Datz N., Endahl L., et al. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind controlled trial. Pediatr Diabetes 2008, 9:554-560.
14. Heise T., Nosek L., Ronn B.B., et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004, 53(6):1614-1620.
15. Cengiz E., Sherr J.L., Erkin-Cakmak A., et al. A bridge to insulin pump therapy: bid regimen with NPH and detemir insulin during initial treatment of youth with type 1 diabetes (T1D). Endocr Pract 2011, 6:1-17.
16. Mooradian A., Bernbaum M., Albert S.G. Narrative review: a rational approach to starting insulin therapy. Ann Intern Med 2006, 145(2):125-134.
17. Cengiz E., Tamborlane W., Martin-Fredericksen M., et al. Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin. Diabetes Care 2010, 33(5):1009-1012.
18. Sherr J., Tamborlane W.V. Past, present, and future of insulin pump therapy: better shot at diabetes control. Mt Sinai J Med 2008, 75(4):352-361.
19. Attia N., Jones T.W., Holcombe J., et al. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care 1998, 21:817-821.
20. Weinzimer S.A., Ahern J.H., Boland E.A., et al. Continuous subcutaneous insulin infusion is safe and effective in infants and toddlers. Diabetes 2003, 52(Suppl 2):A402.
21. Sullivan-Bolyai S., Knafl K., Tamborlane W., et al. Parents' reflections on the use of the insulin pump with their young children. J Nurs Scholarsh 2004, 6:316-323.
22. Moshe P., Battelino T., Rodriguez H., et al. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2007, 30(6):1653-1662.
23. Luijf Y.M., Van Bon A.C., Hoekstra J.B., et al. Premeal injection of rapid acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care 2010, 30(10):2152-2155.
24. Danne T. Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus. Clin Ther 2007, 29(Suppl D):S145-S152.
25. Wolfsdorf J., Crag M.E., Daneman D., et al. Diabetic ketoacidosis in children and adolescents with diabetes. Pediatr Diabetes 2009, 10(Suppl 12):118-133.
26. Boland E.A., DeLucia M., Brandt C., et al. Limitations of conventional methods of self blood glucose monitoring: lessons learned from three days of continuous glucose monitoring in pediatric patients with type I diabetes. Diabetes Care 2001, 24:1858-1862.
27. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care 2010, 33(1):17-20.
28. Writing group for the SEARCH for Diabetes in Youth Study Group Incidence of diabetes in youth in the United States. JAMA 2007, 297(24):2716-2724.
29. Rosenbloom R.L., Silverstein J.H., Amemiya S., et al. Type 2 diabetes in children and adolescents. Pediatr Diabetes 2009, 10(Suppl 12):17-32.
30. Weinzimer S.A., Steil G.M., Swan K.L., et al. Fully automated closed-loop insulin delivery vs. semi-automated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008, 31:934-9390.